Sectors
APUS
Apimeds Pharmaceuticals US, Inc.
3.88
200 x 3.73
100 x 4.06
bid
ask
+
0.01
0.26%
150 @ 06:57 PM
3.80 -0.08 (2.06%)
| Ytd | -76.34% | |
| 1y | -78.80% |
3.73
day range
3.90
3.39
52 week range
59.70
| Open | 4.09 | Prev Close | 3.87 | Low | 3.73 | High | 3.90 | Mkt Cap | 5.86M |
| Vol | 8.18K | Avg Vol | 68.59K | EPS | -35.98 | P/E | N/A | Forward P/E | N/A |
| Beta | 0.15 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.33 | 200-d Avg | 14.79 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 6.28M | ||
| Research and Development Expense | 959.74K | ||
| Selling, General and Administrative Expense | 5.32M | ||
| Operating Income | -6.28M | ||
| Interest Expense | 3.22M | ||
| Net Income | -20.17M | ||
| Net Income Common Stock | -20.17M | ||
| Net Income Common Stock (USD) | -20.17M | ||
| Consolidated Income | -20.17M | ||
| Earnings per Basic Share | -11.77 | ||
| Earnings per Basic Share (USD) | -11.77 | ||
| Earnings per Diluted Share | -11.77 | ||
| Earning Before Interest & Taxes (EBIT) | -16.95M | ||
| Earning Before Interest & Taxes (USD) | -16.95M | ||
| Weighted Average Shares | 1.71M | ||
| Weighted Average Shares Diluted | 1.71M | ||
| Balance Sheet | |||
| Cash and Equivalents | 8.28M | ||
| Cash and Equivalents (USD) | 8.28M | ||
| Investments | 116.74M | ||
| Investments Non-Current | 116.74M | ||
| Trade and Non-Trade Receivables | 115.57K | ||
| Current Assets | 10.68M | ||
| Property, Plant & Equipment Net | 208.09K | ||
| Total Assets | 127.62M | ||
| Debt Current | 14.48M | ||
| Total Debt | 14.58M | ||
| Current Liabilities | 21.07M | ||
| Debt Non-Current | 101.87K | ||
| Total Liabilities | 21.18M | ||
| Accumulated Retained Earnings (Deficit) | -65.63M | ||
| Shareholders Equity | 106.45M | ||
| Shareholders Equity (USD) | 106.45M | ||
| Assets Non-Current | 116.95M | ||
| Total Debt (USD) | 14.58M | ||
| Liabilities Non-Current | 101.87K | ||
| Trade and Non-Trade Payables | 3.22M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 20.28K | ||
| Net Cash Flow from Financing | 3.47M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -701.16K | ||
| Issuance (Repayment) of Debt Securities | 3.39M | ||
| Net Cash Flow from Investing | 1.50M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 1.50M | ||
| Net Cash Flow from Operations | -5.67M | ||
| Share Based Compensation | 105.21K | ||